Fimepinostat治疗复发难治性弥漫大B细胞及高级别B细胞淋巴瘤的2期试验及探索性生物标志物分析
Fimepinostat(CUDC-907)是首创新药口服组蛋白去乙酰化酶和磷脂酰肌醇3激酶抑制剂,在1期研究中显示对复发难治性弥漫大B细胞和高级别B细胞淋巴瘤有效,尤其对MYC蛋白高表达和/或MYC基因改变者。为此开展2期研究,66例可评价患者接受治疗,MYC-IHC≥40%患者(n=46)的主要终点总缓解率为15%。探索性汇总分析显示,MYC改变患者(n=63)总缓解率为22%,其中7例缓解患者持续治疗约2年或更长,VIPER分析得出三蛋白生物标志物分类的阳性和阴性预测值均≥85%。
要点
- Fimepinostat单药在MYC改变的复发难治性DLBCL/HGBL中总缓解率达22%,部分缓解持久。
- MYC-IHC≥40%患者总缓解率为15%,未达更高水平。
- VIPER三蛋白生物标志物分类预测值≥85%,或可指导患者选择。
核心结论
- Fimepinostat单药在MYC改变的复发难治性DLBCL/HGBL中可实现持久缓解,总缓解率22%。
- 联合治疗和/或基于生物标志物的患者选择策略可能提高未来临床试验的缓解率。
研究设计与样本
- 2期研究纳入66例可评价的复发难治性DLBCL/HGBL患者接受Fimepinostat治疗。
- 探索性汇总分析纳入1期和2期研究中MYC改变患者(n=63),并采用VIPER分析生物标志物。
主要发现
- MYC-IHC≥40%患者(n=46)的主要终点总缓解率为15%。
- MYC改变患者(n=63)的总缓解率为22%,其中7例缓解患者持续治疗约2年或更长。
- VIPER分析得出三蛋白生物标志物分类,阳性和阴性预测值均≥85%。
关键数值与推荐
- MYC-IHC≥40%患者(n=46)总缓解率为15%。
- MYC改变患者(n=63)总缓解率为22%,7例缓解持续约2年或更长。
- VIPER三蛋白生物标志物分类的阳性和阴性预测值均≥85%。
临床怎么用
- 对于MYC改变的复发难治性DLBCL/HGBL,Fimepinostat单药可作为探索性治疗选择。
- VIPER三蛋白生物标志物分类或有助于筛选可能获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fimepinostat (CUDC-907), a first-in-class oral small-molecule inhibitor of histone deacetylase and phosphatidylinositol 3-kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high-grade B-cell lymphomas (DLBCL/HGBL), particularly those with increased MYC protein expression and/or MYC gene rearrangement/copy number gain (MYC-altered disease). Therefore, a phase 2 study of fimepinostat was conducted in this patient population with 66 eligible patients treated. The primary end-point of overall response (OR) rate for patients with MYC-IHC ≥40% (n = 46) was 15%. Subsequently, exploratory pooled analyses were performed including patients treated on both the phase 1 and 2 studies based upon the presence of MYC-altered disease as well as a biomarker identified by Virtual Inference of Protein activity by Enriched Regulon analysis (VIPER). For these patients with MYC-altered disease (n = 63), the overall response (OR) rate was 22% with seven responding patients remaining on treatment for approximately two years or longer, and VIPER yielded a three-protein biomarker classification with positive and negative predictive values of ≥85%. Prolonged durations of response were achieved by patients with MYC-altered R/R DLBCL/HGBL treated with single-agent fimepinostat. Combination therapies and/or biomarker-based patient selection strategies may lead to higher response rates in future clinical trials.
引用
- Landsburg DJ, Barta SK, Ramchandren R, et al. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol. 2021. PMID: 34341990. doi:10.1111/bjh.17730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。